A Message from Huge Alerts 
Little-known biotech company is making waves for its unique involvement in the regenerative medicine landscape. Regenerative medicine continues to find its way into the mainstream…. It’s an exciting topic on Wall Street. Enormous amounts have been invested in stem cell therapy research for decades. This Stock may be flying under the radar right now, but could soon gain major attention for what it is uniquely doing. The company harnesses elements of perinatal tissue derived from the human placenta for manufacturing structural tissue allografts to heal wounds. Its products have the potential to save millions of lives while building market capitalization growth in the process. Excitingly they have been approved for an Investigational Review Board (IRB) sanctioned clinical study. This study aims to investigate the utilization and effects of the company’s Vendaje line in diabetic patients suffering from foot ulcers. VENDAJE, a dehydrated placental allograft that can be used for advanced wound care as a substitute for skin grafts or placed over open wounds to speed up and improve the healing process after surgery. Diabetic Foot Ulcers are a significant risk for people with diabetes. According to the American Podiatric Medical Association (APMA), a leading resource for foot and ankle health, approximately 15 percent of people with diabetes develop foot ulcers. Of those 15 percent, six percent go on to be hospitalized due to infection or other ulcer-related complications. The risk to patients with diabetes is significant, as it is the leading cause of lower extremity amputations in the U.S. Approximately 14 to 24 percent of people with diabetes who develop foot ulcers will require an amputation. Learn how (OTC:BSEM) is demonstrating that its process is scientifically exceptional and how it could dominate in a multi-billion-dollar market! | 
Tidak ada komentar:
Posting Komentar